Keys to Supportive Care in Pancreatic Cancer: Early Palliative Care, Improved Communication

OncologyONCOLOGY Vol 27 No 3
Volume 27
Issue 3

Optimal supportive care for patients with pancreatic cancer is essential. Putting these interventions into practice requires that oncologists and oncology teams incorporate innovations at both the individual and the system level.

The article by Torgerson and Wiebe in this issue of ONCOLOGY provides an excellent guide to medical management of the supportive care issues involved in pancreatic cancer. If all patients with this complex illness were managed as carefully as described by these authors, I suspect that general quality of life would clearly improve. The question I will address in this commentary is, how could we improve the way these issues are managed in busy outpatient oncology clinics?

One method of addressing supportive care issues is to involve an integrated palliative care team from the time of diagnosis. Although this has not been reported specifically for pancreatic cancer, Temel and others have reported a variety of benefits that sprang from the early involvement of an interdisciplinary palliative care team for patients with metastatic non−small-cell lung cancer.[1] Notably, the palliative care consultation team worked physically within the oncology clinic, ensuring ongoing communication and collaboration, and saw patients frequently. The benefits of early palliative care delivered in this way included improved quality of life, reduced symptom burden, better mood, and increased survival. Follow-up analyses of this randomized study showed that patients on the palliative care intervention arm received slightly less intravenous chemotherapy[2] and had better prognostic awareness over the course of their illness.[3]

Another key ingredient in helping our patients and their families hope for the best, prepare for the worst, and partner effectively with the oncology team is to improve clinicians’ communication skills. Patients and families clearly value what they hear from their oncologists, yet the communication they receive is often muddled. In one study of oncology fellows, for example, less than 20% used the word “cancer” in disclosing a cancer recurrence to a standardized patient.[4] Oncologists frequently overlook emotional cues, and in one large observational study, oncologists made empathic responses in only 11% of their visits with patients who had advanced cancers.[5]

There is clear evidence, however, that communication skills can be improved with training. Fallowfield documented substantial improvements in a large randomized study of senior oncologists in the UK.[5] Back demonstrated even larger improvements in a pre/post study of US oncology fellows,[6] and recently Tulsky demonstrated improvements in oncologist empathy and subsequent patient trust after a CD-ROM-based training intervention.[5]

The new frontier for this work is to involve oncology teams. Current practice patterns involve frequent handoffs between oncologists, advanced practice practitioners, nurses, social workers, nutritionists, chaplains, and others. The challenge is to create interprofessional communication that seems to the patient and family like a single continuous conversation, and for the team to create a channel for background communication that enables each professional to approach the patient and family in an up-to-the-minute way. Fallowfield has already reported early efforts in defining what is needed for teams.[7]

Optimal supportive care for patients with pancreatic cancer is essential. Putting these interventions into practice requires that oncologists and oncology teams incorporate innovations at both the individual and the system level.

Financial Disclosure:The author has no significant financial interest or other relationship with the manufacturers of any products or providers of any service mentioned in this article.



1. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363:733-42.

2. Greer JA, Pirl WF, Jackson VA, et al. Effect of early palliative care on chemotherapy use and end-of-life care in patients with metastatic non-small-cell lung cancer. J Clin Oncol. 2012;30:394-400.

3. Temel JS, Greer JA, Admane S, et al. Longitudinal perceptions of prognosis and goals of therapy in patients with metastatic non-small-cell lung cancer: results of a randomized study of early palliative care. J Clin Oncol. 2011;29:2319-26.

4. Back AL, Arnold RM, Baile WF, et al. Efficacy of communication skills training for giving bad news and discussing transitions to palliative care. Arch Intern Med. 2007;167:453-60.

5. Tulsky JA, Arnold RM, Alexander SC, et al. Enhancing communication between oncologists and patients with a computer-based training program: a randomized trial. Ann Intern Med. 2011;155:593-601.

6. Fallowfield L, Jenkins V, Farewell V, et al. Efficacy of a Cancer Research UK communication skills training model for oncologists: a randomised controlled trial. Lancet. 2002;359:650-6.

7. Fleissig A, Jenkins V, Catt S, Fallowfield L. Multidisciplinary teams in cancer care: are they effective in the UK? Lancet Oncol. 2006;7:935-43.

Related Videos
An expert from the University of California, Los Angeles suggests that the NALIRIFOX may be a beneficial treatment for patients with pancreatic ductal adenocarcinoma.
Patients with metastatic pancreatic ductal adenocarcinoma who receive NALIRIFOX tend to have more gastrointestinal toxicity while nab-paclitaxel/gemcitabine results in more cytopenias, according to an expert from University of California, Los Angeles.
An expert from the University of California, Los Angeles described the purpose and design of the phase 3 NAPOLI-3 study, assessing NALIRIFOX in metastatic pancreatic ductal adenocarcinoma.
Data from a ctDNA analysis of the phase 3 INTRIGUE study indicate that KIT mutational status may be associated with response to certain Tyrosine kinase inhibitors in GIST, according to an expert from the Yale Cancer Center in New Haven, Massachusetts.
Future research into the management of unresectable hepatocellular carcinoma may involve combining local therapies with checkpoint inhibitors like durvalumab and tremelimumab, according to Ghassan K. Abou-Alda, MD.
Patients with unresectable hepatocellular carcinoma who have recurrent disease following surgery or locally advanced diseases who will likely progress on local therapy may have an opportunity to benefit from tremelimumab and durvalumab following its FDA approval, according to Ghassan K. Abou-Alfa, MD.
Ghassan K. Abou-Alfa, MD, discusses the importance of improving access to novel therapies and combinations for patients with hepatocellular carcinoma across the world.
Ghassan K. Abou-Alfa, MD, spoke about the recent approval of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma, based on results from the phase 3 HIMALAYA trial.
Related Content